Dozens of patients have taken legal action against drug manufacturers, filing personal injury lawsuits that allege they were not adequately...

The condition is part of a list of areas, including addiction and menopause, where Novo sees potential overlap with either its core scienti...

Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating ...

The Danish drugmaker will initially test Anthropic models and Claude Science in its research and development workflows, and address scienti...

Eli Lilly's Mounjaro received FDA approval for reducing heart attack and stroke risks. This new indication expands its use beyond diabetes ...

Eli Lilly has launched its oral weight management pill Foundayo in the United Kingdom. This new treatment, chemically known as orforglipron...

Nestle is developing specialized products for GLP-1 weight-loss drug users. Artificial intelligence aids in analyzing research and identify...

Britain has become the first country in Europe to approve orforglipron, the oral weight loss and diabetes treatment developed by US company...

Britain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the ...

Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline afte...

Wegovy pill: Novo Nordisk is launching the first oral GLP-1 pill for weight loss, offering a more affordable alternative to injections. The...

Novo Nordisk has slashed Wegovy prices in India by nearly 40 percent. This move has dramatically increased sales volume by 70 percent in No...

Hims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. Th...

A latest study has shown promising results in people suffering from metabolic dysfunction-associated steatohepatitis (MASH), an advanced fo...

Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to outperform El...

Novo Nordisk plans to bring its weight-loss drug, Wegovy, to India in 2026. The company aims to secure regulatory approvals and ensure suff...

In a groundbreaking achievement, Novo Nordisk's obesity medication Wegovy has not only demonstrated its efficacy in substantial weight loss...